SAN FRANCISCO—January 26, 2015—Invitae Corporation, a genetic information company, announced today that it had reached a settlement with Myriad Genetics, Inc., the University of Utah Research Foundation, the Trustees of the University of Pennsylvania, HSC Research and Development Limited Partnership, and Endorecherche, Inc. in their patent dispute concerning Invitae’s genetic testing for the BRCA1, BRCA2 and MUTYH genes (MDL Case No. 2:14-CV-02510; Civil Case No. 2:14-cv-00153-RJS (D. Utah).)
The parties agreed to dismiss with prejudice their claims and counterclaims against each other in this action, that Invitae would be granted a covenant not to sue with respect to the patents–in–suit, and that the parties would bear their own costs. This settlement will resolve all pending litigation between Invitae and the other parties.
Based in San Francisco, Invitae’s mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Currently focused on hereditary cancers, Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time and lower price than many single-gene tests today. The company currently provides a single diagnostic test comprising over 200 genes for a variety of genetic disorders associated primarily with cancer, but also covering cardiology, hematology, neurology and pediatrics.